Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 20... (9 decreased slightly to $98.2 million. ...)

Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook

Date:4/30/2009

9 decreased slightly to $98.2 million. Brand other revenue decreased $2.5 million to $13.8 million.

Brand selling and marketing expense for the first quarter of 2009 increased 32 percent to $36.9 million, due primarily to preparation for the launches of Rapaflo(TM) and Gelnique(TM). Watson's urology sales force began promoting Rapaflo(TM) on April 7, 2009 and our specialty salesforce will begin promoting Gelnique(TM) in May 2009.

    Distribution Segment Information

                                       Three Months Ended
                                            March 31,
                                          ------------
    (Unaudited; $ in millions)            2009    2008
                                          ----    ----
    Distribution Segment Contribution
      Net revenue                        $153.7  $144.9
      Cost of sales                       126.0   122.9
                                          -----   -----
        Gross profit                       27.7    22.0
                                           ----    ----
        Gross margin                       18.0%   15.2%
      Selling and
       marketing                           16.1    14.0
                                           ----    ----
        Segment
         contribution                     $11.6    $8.0
                                          =====    ====
        Segment margin                      7.5%    5.5%

Distribution segment net revenue for the first quarter of 2009 increased six percent or $8.8 million to $153.7 million. The increase was primarily due to sales of new products. Distribution revenue excludes sales of Watson products.

Distribution segment gross margin was 18.0 percent in the first quarter of 2009 compared to 15.2 percent in the first quarter 2008 and 15.6 percent in the fourth quarter of 2008. The increase in gross margin was prim
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds

Post Your Comments:

(Date:12/16/2009)... Dec. 16 HealthSciences Institute will ... care professionals, teams and organizations who serve ... chronic diseases in employer, health plan, medical ... collaborative will offer free, noncommercial webinars on ... disease prevention, management and care improvement. Each ...

(Date:12/16/2009)... Trust Sanger Institute announce the first comprehensive analyses of ... mutations in the DNA of cancer cells which are ... malignant melanoma and a lung cancer, reveal for the ... of two cancers. , Lung cancer causes around one ... with smoking. The number of mutations found suggest that ...

(Date:12/16/2009)... Newborn-Safe Skin Care Products from Episencial Offers Planet-Friendly Organics, Solar-Powered ... , ... Los Angeles, CA (PRWEB) ... now have an authentic, affordable choice in all natural skin ... its eponymous product line for young children featuring the beloved ...

(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...

(Date:12/16/2009)... 8 percent of children are uninsured, government report finds ... first six months of this year, 45.4 million Americans ... population -- had no health insurance, according to new ... addition, 58.4 million (19.4 percent) people of all ages ... year prior to the interview, and 31.9 million (10.6 ...

Breaking Medicine News(10 mins):Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3 Health News:Lung cancer and melanoma laid bare 2 Health News:Lung cancer and melanoma laid bare 3 Health News:Lung cancer and melanoma laid bare 4 Health News:Lung cancer and melanoma laid bare 5 Health News:Lung cancer and melanoma laid bare 6 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4 Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5 Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2 Health News:Over 45 Million Americans Now Lack Health Insurance 2

[1] New Learning Collaborative to Prepare Clinicians for Better Chronic Care [1] Lung cancer and melanoma laid bare [1] New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" [0] With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 [1] Over 45 Million Americans Now Lack Health Insurance

... The Cystic Fibrosis Foundation reported today that key indicators ... lung function and nutritional status -- are rising nationwide ... the outlook for people with CF continues to improve ... due to quality improvement programs spearheaded by the CF ...

... 28 The newest product offered by,Terumo ... Terumo Interventional Systems announces the launch ... the occlusion of blood,vessels, vascular malformations, and ... embolization system with a hydrogel coating that ...

... 28 The following letter is,being released by CEL-SCI ... Dear Fellow Shareholders:, Our Company underwent a wonderful ... development to a late-stage biotechnology,company. We are now one ... a,completely novel medicine with blockbuster potential ready to go ...

... is the latest American Chemical Society (ACS) News Service Weekly ... & Engineering News.,Please credit the individual journal or the American ... CONTENT IS FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is ... , ARTICLE #1 FOR IMMEDIATE RELEASE ...

... Research Institute (CRI) announced today that it has brought ... Sabin Vaccine Institute, and the Cancer Vaccine Collaborative, a ... Ludwig Institute for Cancer Research (LICR), to form the ... a unified voice in the cancer vaccine field and ...

... 4:30 p.m. Eastern Time -, SAN FRANCISCO, Jan. ... that, based on its end-of-Phase 2 meeting,with the U.S. ... a pivotal confirmatory Phase 3 trial of Dimebon(TM) for,mild-to-moderate ... The FDA informed Medivation that the company,s previously completed,trial ...

Cystic Fibrosis Foundation reports upward trend for key health outcomes Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology CEL-SCI Corporation Releases Letter to Shareholders American Chemical Society's weekly PressPac -- Jan. 23, 2008 Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008

(Date:12/16/2009)... 16 Siemens Healthcare today ... to help healthcare ... deadlines defined within the HITECH provision of ... Featuring zero-percent interest terms for ... defer up-front payments associated with their technology ...

(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...

(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...

Breaking Medicine Technology:Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2 Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3 Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4 BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2 BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3 BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4 MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2 MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3 MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4 New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 1 New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 2 Aon Declares Quarterly Dividend 59320 1 Aon Declares Quarterly Dividend 59320 2 Hogs n Hens for Hope NCPC BBQ Cook Off 26amp 3B Festival October 17 at Duplin County Events Center Features Fun for the Whole Family and Benefits Laz 59317 1 Hogs n Hens for Hope NCPC BBQ Cook Off 26amp 3B Festival October 17 at Duplin County Events Center Features Fun for the Whole Family and Benefits Laz 59317 2

[0] Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use [0] BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease [0] MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices

... Assess Safety and Dose-Sparing Capability of Iomai Adjuvant ... ... Corporation,(Nasdaq: IOMI ) today announced that it has begun dosing in ... the,company,s immunostimulant patch when used in combination with an injected,H5N1 influenza vaccine. ...

... ANN ARBOR, Mich., Sept. 6 Terumo Heart ... Launch Symposium at the European,Association of Cardio-Thoracic Surgeons ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO ... ) A summary of the European ...

Other Medicine Technology:Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 2 Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 3 Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 4 Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September 2

Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September

... Ophthalmoscope with superior aspherical optics. The separation ... of the aspherical optical system avoids corneal ... allows you to view the whole of ... with a small pupil. Conventional ophthalmoscopes often ...

... Heine Beta 200S is the ... a combination of patented aspherical ... a range of corrective lenses ... in single diopter steps. A ...

With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....

... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...

Medicine Products:

3.5V Beta 200 M2 2.5V Heine Beta 200S 2.5V Autofoc 2 Ophthalmoscope 2.5V Ophthalmic BETA 200 Pro

Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 20...(9 decreased slightly to $98.2 million. ...),Health